You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 201491 - 201500 of 207728 results
  1. Development of Therapeutic Pan-Filovirus Macaque Monoclonal Antibodies

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Filoviruses, Ebola (EBOV) and Marburg (MARV), are causative agents of sever hemorrhagic fever in humans with case-fatality rates exceeding 88%. Filoviruses, designated as category A select agents by the Centers for Disease Control and Prevention, are considered potential biowarfare agents and therefore a serious threat to public health and national security. Fu ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  2. Biological vector control reducing arboviruses, including Dengue and Chikungunya

    SBC: MosquitoMate, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): In the absence of effective, approved vaccines or therapeutic measures against dengue and other mosquito borne pathogens, public health efforts must focus on the control of mosquito vectors that are required for transmission. Unfortunately, effective control measures are not available against the invasive and medically important Asian Tiger Mosquito (Aedes albo ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  3. TARGETABLE BACTERICIDAL PROTEINS TO SPECIFICALLY KILL CLOSTRIDIUM DIFFICILE BACTE

    SBC: AvidBiotics Corp.            Topic: NIAID

    DESCRIPTION (provided by applicant): The ultimate goal of this proposal and any subsequent phase II proposal is to develop a unique protein agent to prevent Clostridium difficile associated diseases in those patients at high risk rather than wait to treattheir dangerous and costly infections. We aim in this SBIR phase I project to determine the feasibility of oral delivery of a lead, specifically ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Protease-resistant D-peptide inhibitors of RSV entry

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Respiratory syncytial virus (RSV) is the major cause of severe lower respiratory tract infections in children and infants, affecting an estimated 64 million people and causing 160,000 deaths worldwide per year (WHO). Each year in the United States, ~100,000 infants and ~170,000 adults are hospitalized due to RSV infection. High-risk adults (elderly and patients ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Development of Sulfamoylbenzamide Derivatives as Antiviral Agents against HBV Inf

    SBC: Enantigen Therapeutics            Topic: NIAID

    DESCRIPTION (provided by applicant): This is a proposal to develop newly discovered sulfamoylbenzamide derivatives as therapeutic agents for the treatment of chronic hepatitis B virus (HBV) infection. These molecules have been identified as inhibitors of HBV pregenomic (pg) RNA encapsidation, a critical step in the life cycle of HBV. PgRNA is the template for reverse transcriptional replication of ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  6. Rapid Comprehensive Identification of Pneumonia Pathogens

    SBC: IDAHO TECHNOLOGY            Topic: NIAID

    DESCRIPTION (provided by applicant): Lower respiratory tract infections (LRTI), including pneumonia, are a significant threat to human health. For example, community-acquired pneumonia and influenza are together the seventh leading cause of death in the United States. There is a wide range of pathogens that can cause pneumonia. Defining the causative organism in pneumonia, however, is complex. St ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Treatment of Cytomegalovirus by Inhibition of Host Lipid Synthesis

    SBC: Kadmon Corporation, LLC            Topic: NIAID

    DESCRIPTION (provided by applicant): Cytomegalovirus (CMV) causes significant disease and mortality in populations with weakened immune systems, including cancer patients, organ transplant recipients, and HIV-infected people. Additionally, it is the most common cause of congenital infection affecting about 1% of all live births worldwide, causing 20-30% of infants infected in utero to develop birt ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  8. Treatment of Wound Infection with Novel Uncharged Silver Carbene Complexes

    SBC: Iasis Molecular Sciences INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Three novel uncharged silver carbene microbicides that have been shown to be effective against a wide variety of pathogens will be formulated into two different ointment formulations and tested in an infected healing model in the diabetic rat. Formulation of the silver carbenes into one of either a transparent (gel) wound ointment that will allow viewing of the ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  9. Development of a Recombinant Subunit Vaccine for CCHF

    SBC: HAWAII BIOTECH, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Emerging and reemerging infectious diseases continue to pose serious health threats world-wide. Consequently, the development of measures to mitigate the natural, as well as potential bioterrorist threats of these infectious diseases is an important endeavor. The NIAID Strategic Plan for Biodefense Research is specifically directed at promoting research that ca ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  10. A novel Structure Based Vaccine for staphylococcal alpha hemolysin

    SBC: Integrated Biotherapeutics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Staphylococcus aureus is a gram positive human pathogen that causes a wide range of infections ranging from skin and soft tissue infections to life threatening diseases like sepsis and pneumonia. S. aureus is well knownfor its ability to acquire and evolve resistance mechanisms towards antimicrobial agents and meanwhile there are resistances towards all antibio ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government